Policy Bulletins
The Policy Bulletins listed below represent our catalogue of medical and claim payment policies. If you are looking for a specific type of policy, choose a category from the menu on the right. You may also use the search function in the top menu to search for policies by word or phrase.
   


Policy #
Policy Bulletin Title
Show details for
08.00.62i
Abatacept (Orencia®) for Injection for Intravenous Use
Show details for
08.01.11e
Ado-Trastuzumab Emtansine (Kadcyla®)
08.00.69b
Agalsidase beta (Fabrazyme®)
08.01.22c
Alemtuzumab (Lemtrada®)
08.00.72h
Alglucosidase alfa (e.g., Lumizyme®)
08.00.91d
Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP™, Glassia™, Zemaira™)
Show details for
08.01.41c
Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)
08.01.35b
Asparaginase Erwinia Chrysanthemi (Erwinaze®)
08.00.99b
Belimumab (Benlysta®) for Intravenous Use
Show details for
08.00.66m
Bevacizumab (Avastin®) and Related Biosimilars
08.01.21c
Blinatumomab (Blincyto®)
08.00.73l
Bortezomib (Bortezomib for Injection, Velcade®)
Show details for
08.00.26v
Botulinum Toxin Agents
Show details for
08.01.13d
Brentuximab Vedotin (Adcetris®)
08.01.49a
Burosumab-twza (Crysvita®)
08.00.96d
Cabazitaxel (Jevtana®)
08.01.51
Canakinumab (Ilaris®)
08.01.05f
Carfilzomib (Kyprolis™)
08.01.39c
Cerliponase alfa (Brineura®)
Show details for
08.00.67l
Cetuximab (Erbitux®)
Show details for
08.01.43e
Chimeric Antigen Receptor (CAR) Therapy
08.00.92aa
Coagulation Factors
08.01.08d
Coverage of Prescription Oral Anticancer Drugs and/or Biologics as Provided Under the Company's Medical Benefit
08.01.29e
Daratumumab (Darzalex™)
Show details for
08.00.94m
Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity™)
08.01.24
Deoxycholic Acid (Kybella™)
08.00.49e
Dofetilide (Tikosyn®) Use in the Inpatient Setting
08.01.37a
Drugs Used for the Maintenance Treatment of Opioid or Alcohol Use Disorder (e.g., Naltrexone Implants, Probuphine Implant, Sublocade Injection, Vivitrol Injection)
08.00.84f
Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™)
08.01.42a
Edaravone (Radicava™)
08.01.54b
Emapalumab-lzsg (Gamifant®)
08.00.51j
Enzyme Replacement for the Treatment of Gaucher's Disease
08.01.26b
Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., pegademase bovine [Adagen®], elapegademase-lvlr [Revcovi™])
08.00.70e
Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
Show details for
08.00.98e
Eribulin Mesylate (Halaven®)
08.00.75n
Erythropoiesis-Stimulating Agents (ESAs)
08.00.12
Fam-trastuzumab deruxtecan-nxki (Enhertu®)
Show details for
08.01.15d
Golimumab (Simponi Aria®) Intravenous (IV) Injection
08.01.33b
Gonadotropin-Releasing Hormone Agonist (Eligard®, Lupron Depot®)
08.01.00g
Hydroxyprogesterone Caproate Injection as a Technique to Reduce the Risk of Preterm Birth in High-Risk Pregnancies
08.01.46a
Ibalizumab-uiyk (Trogarzo™)
Show details for
08.00.13v
Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
08.00.22m
Immune Prophylaxis for Respiratory Syncytial Virus (RSV)
08.01.04v
Immunizations
Show details for
08.00.34m
Infliximab and Related Biosimilars
08.01.23f
Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®)
Show details for
08.00.74m
Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists and Related Biosimilars
Show details for
08.01.01i
Ipilimumab (Yervoy®)
Show details for
08.01.40b
Lanreotide (Somatuline® Depot)
08.00.10
Luspatercept–aamt (Reblozyl®)
08.01.57
Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)
08.01.52b
Mogamulizumab-kpkc (Poteligeo®)
08.01.53b
Moxetumomab Pasudotox-tdfk (Lumoxiti™)
08.00.64g
Natalizumab (Tysabri®)
08.01.36d
Nusinersen (Spinraza®)
Show details for
08.00.18m
Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk
08.01.38c
Ocrelizumab (Ocrevus®)
Show details for
08.01.10e
Octreotide Acetate (Sandostatin® LAR Depot)
08.00.88f
Ofatumumab (Arzerra®)
08.00.15e
Off-label Coverage for Prescription Drugs and/or Biologics
Show details for
08.00.55h
Omalizumab (Xolair®)
Show details for
08.00.90j
Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound)/(Abraxane® for Injectable Suspension)
08.01.50b
Patisiran (Onpattro™)
Show details for
08.01.32a
Pegfilgrastim (Neulasta®) and Related Biosimilars
Show details for
08.01.02e
Pegloticase (Krystexxa®)
Show details for
08.00.87f
Pemetrexed (Alimta®)
08.00.95d
Personalized Vaccines (e.g. Provenge®)
Show details for
08.01.07f
Pertuzumab (Perjeta®)
08.01.59b
Polatuzumab Vedotin-Piiq (Polivy™)
Show details for
08.00.83h
Pralatrexate (Folotyn®) for Injection
Show details for
08.01.20j
Programmed Death Receptor-1 (PD-1) Antagonists (e.g., Keytruda®, Opdivo®) and Programmed Death-Ligand 1 (PD-L1) Antagonists (e.g., Tecentriq®, Bavencio®, Imfinzi™)
Show details for
08.00.08j
Radioimmunotherapy with Ibritumomab Tiuxetan (Zevalin®) (Independence Administrators)
08.01.14e
Radium Ra 223 dichloride (Xofigo®) Injection (Independence Administrators)
08.01.25d
Ramucirumab (Cyramza®)
08.01.12b
Repository Corticotropin (H.P. Acthar® Gel Injection)
Show details for
08.00.50t
Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
08.01.28c
Sebelipase alfa (Kanuma®)
Show details for
08.00.78ad
Self-Administered Drugs
08.01.19f
Siltuximab (Sylvant®)
08.01.55b
Tagraxofusp-erzs (Elzonris™)
08.01.48b
Tildrakizumab-asmn (Ilumya™)
Show details for
08.00.85h
Tocilizumab (Actemra®) for Intravenous Infusion
08.00.17h
Total Parenteral Nutrition (TPN) / Intradialytic Parenteral Nutrition (IDPN) / Intraperitoneal Parenteral Nutrition (IPN)
Show details for
08.00.33n
Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)
Show details for
08.00.25l
Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
08.00.57n
Treatments for Complex Regional Pain Syndrome (CRPS)
08.01.47a
Triamcinolone Acetonide Extended-Release Injectable (Zilretta™)
08.00.82k
Ustekinumab (Stelara®)
Show details for
08.01.18d
Vedolizumab (Entyvio®)
08.01.44c
Voretigene Neparvovec-rzyl (Luxturna™)

Connect with Us        


© 2017 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.